Xeltis exceeds 50% enrollment in US Pivotal trial for aXess™, its vascular access device for hemodialysis
- US pivotal trial is a multi-center study evaluating a bioabsorbable hemodialysis vascular access implant across complex hemodialysis patients representing real-world practice
- > 50% of target enrollment reached across 20 sites in the United States
EINDHOVEN, The Netherlands – 2 July, 2026 – Xeltis, a leading developer of transformative implants that enable the natural creation of living and long-lasting vessels, today announces that it has exceeded 50% enrollment in its US pivotal trial for aXess™, its vascular access device that transforms into a living vessel for reliable hemodialysis access in adults with end-stage renal disease (ESRD).
